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ejection function, and that impaired contractile function may not
be irreversible in all these patients. As Essop mentions, Wisen-
baugh (7) reported that, among patients with mitral regurgitation,
10 of 14 with ejection fraction 0.60 and 4 of 13 with ejection
fraction 0.60 had muscular dysfunction and that others did not.
His results and ours clearly show that LV dysfunction cannot be
predicted with ejection fraction alone. It may be important to us to
acknowledge that ejection fraction decreases after surgery in
general, but that in some patients it can increase owing to
improved contractility.
Finally, among 171 patients in our analysis of LV dysfunction,
65 patients had moderate mitral regurgitation, and 106 patients
had severe mitral regurgitation.
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Composite Confusion
In their retrospective post hoc analysis of the CADILLAC study,
Dr. Cox et al. (1) state that the one-year composite adverse event
rate (death, reinfarction, disabling stroke, or target vessel revascu-
larization [TVR]) was greater after optimal percutaneous translu-
minal coronary angioplasty (PTCA) than routine stenting (21.9%
vs. 13.8%, p  0.001) and that this was driven largely by increased
rates of ischemic TVR (19.1% vs. 9.1%, p  0.001). As a result,
they conclude that early and late outcomes can be further improved
with routine stent implantation.
The conclusion seems excessive given results glossed over as
simply nonsignificant. Perhaps what the investigators might have
stated was that the difference in the composite outcome was driven
entirely by the least clinically relevant and softest outcome event,
namely TVR. Indeed, as shown in Table 3 of their study, the risks
of death, recurrent myocardial infarction (MI), and disabling
stroke were all higher (but not statistically significantly so) with
stenting at 30 days. Moreover, at one year the relative increase in
the risk of death with stenting was 31.3% and the absolute increase
was 1.0%; this is about the same as the benefit of tissue plasmin-
ogen activator over streptokinase and far larger than any putative
benefit of glycoprotein IIb/IIIa inhibitors in acute coronary syn-
dromes. I cannot help but believe that had the estimates for the
individual outcome events been reversed (that is, favoring stenting)
readers would have seen phrases such as “strong trends” or “lack of
statistical power” as an explanation. This worrisome increase in
clinically important outcome events, also seen in other studies of
stents in MI, should not be dismissed as just play of chance or as
not significant. I would have thought it might merit a line or two
in the discussion.
Could the investigators please provide readers with the differ-
ences between stent and optimal PTCA groups for: 1) death and
disabling stroke, and 2) death, disabling stroke, and recurrent MI
at 30 days and at 1 year?
Finally, should we not discard this silly notion of composite end
points that equate a death and a disabling stroke as equivalent to
a recurrent revascularization procedure? Is that how our patients
view these events? Interpretive difficulties are sure to arise in
problematic reports, such as the study by Cox et al. (1), where
elements of the composite go in opposite directions (the treatment
reduces TVR, but death, disabling stroke, and recurrent MI may
be increased) (2). Careful wordsmithing often gives the illusion
that all elements of the composite end point are favorably affected
(3).
In the absence of a consensus-weighting scheme for elements of
a composite, perhaps we need a hierarchical nomenclature for
composites that make the results more transparent, particularly in
the published abstract. For example, one could state that the
composite was significantly lower among patients randomized to
stenting (21.9% vs. 13.8%, p  0.001, death [inc-ns], disabling
stroke [inc-ns], re-MI [nd-ns], TVR [dec-sig]). All elements of
the composite are reported, and they are ranked starting with death
and followed by those of lesser clinical importance. Those elements
deemed to be hard and objective are capitalized, whereas those that
are more subjective or clinician-driven are given in lowercase. It is
specified whether the point estimate is in keeping with an increase
(inc), decrease (dec), or no difference (nd); and whether there is
conventional statistical significance (sig) or not (ns).
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REPLY
We thank Dr. Massel for his interest in our study (1), and though
we agree with some of his points, there is one major flaw with his
reasoning: The optimal percutaneous transluminal coronary angio-
plasty (PTCA) group was defined in the study as having near
perfect angiographic results, whereas the routine stent group as
defined included all patients, whether or not an optimal (or even
successful!) result was obtained. Most pertinently, 100% of patients
in the optimal PTCA group achieved Thrombolysis In Myocardial
Infarction (TIMI) flow grade 3 (by definition), compared to only
95.7% of patients in the routine stent group (p  0.0001), clearly
explaining the weak trends toward increased mortality Massel
notes. In light of this unfair playing field, it is particularly
noteworthy that the benefits of stents in reducing restenosis and
infarct artery reocclusion are still strongly apparent. As we stated in
the Limitations section of our report, our data are hypothesis
generating only; an adequately powered randomized trial of stent-
ing versus no stenting in patients achieving optimal PTCA results
is required to definitely address this issue. Such a study, the
Florence Randomized Elective Stenting in Acute Coronary Oc-
clusions (FRESCO) trial, was performed in a relatively small
number of patients (n  150) undergoing primary angioplasty
using now obsolete first-generation stents, demonstrating not only
marked reductions in clinical and angiographic restenosis, but also
nonsignificant reductions toward reduced rates of mortality and
reinfarction (2).
Where we do agree with Massel is in our disdain for composite
end points. Although at times a necessary evil to allow realistic
sample sizes in randomized trials, they may obscure the forest for
the trees. Hierarchical rankings, unfortunately, introduce as many
new problems and vagaries as they solve. A balanced perspective
can usually be obtained through careful consideration of the
patient populations and methods, and by judicious examination of
all component end points. Finally, as important as it is to
understand beta error (realizing that real differences between
groups may not become statistically apparent with small sample
sizes), it is equally vital to recognize that small sample sizes can also
by chance suggest possible differences (or even large treatment
effects) where none exist.
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Characteristics of a Great Review
I found myself reacting to the Editor’s Page describing the
characteristics of an excellent manuscript peer review in a recent
issue of the Journal (1) with great surprise—surprise that these
characteristics had not previously been so carefully considered and
clearly communicated.
Dr. DeMaria states that “an excellent review is one that is
objective and constructive, one that avoids antagonism and points
out areas in which the article can be improved.” I would suggest
that this might be rephrased as, “One should write reviews one
would be happy to receive.” Far too many reviews are caustic and
derisive. They serve the medical literature poorly and can be
especially destructive to young researchers. It is not too much to
expect that a review be as dispassionately scientific as the work that
is being reviewed. The suggestions made by the editors of JACC
deserve widespread adoption.
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